Globe Newswire

HAMILTON, Bermuda, May 03, 2024 (GLOBE NEWSWIRE) -- Enstar Group Limited (“Enstar”) (Nasdaq: ESGR) today announced that it will pay cash dividends on its Series D and Series E preference shares.

Dividends on Enstar’s Series D 7.00% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares of $0.43750 per depositary share (each of which represents a 1/1,000th interest in a Series D Preference Share) will be payable on June 3, 2024 to shareholders of... (continue reading...)

Schedules Conference Call and Webcast

OLD GREENWICH, Conn., May 03, 2024 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON), a leading global talent solutions company, will issue its first quarter financial results for the period ended March 31, 2024, before the market opens on Friday, May 10, 2024.

The company will host a conference call to review its results that same day at 10:00 am ET (7:00 am PT). If you wish to join the conference call, please use the... (continue reading...)

ATHENS, Greece, May 03, 2024 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE: GSL) (the “Company”) has scheduled its Annual Meeting of Shareholders for June 17, 2024, at 10:00 a.m. Eastern Time (the “Annual Meeting”). The record date for determining shareholders entitled to participate at the Annual Meeting is April 18, 2024. The business of the Annual Meeting is to elect three Term I Directors to serve until the 2027 Annual Meeting of Shareholders and to... (continue reading...)

SCOTTSDALE, Ariz, May 03, 2024 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today advises that its audited consolidated financial statements for the fiscal year ended December 31, 2023, included in the Company’s Annual Form on Form 10-K filed with the Securities and Exchange Commission... (continue reading...)

DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 528,000 shares of the Company's... (continue reading...)